Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Prescient Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform
Health & Biotech
Chimeric IPO: What ASX stockspert Bhavdip143 likes so much about the $35m CAR T play
Health & Biotech
How CAR T cancer treatment saved Laurie Adami’s life
News
Last Orders: What you might have missed on the ASX today
Health & Biotech
How CAR-T uses the body’s own immune system to fight cancer
News
Last Orders: What you might have missed today on the ASX
Stockhead TV
ASX small caps leading the fight against cancer
Health & Biotech
Dr Boreham’s Crucible: Why Prescient now has ‘substance and sizzle’
Health & Biotech
Sophisticated and professional investors line up to give Prescient Therapeutics cash
Health & Biotech
Health Kick Podcast: Chemo’s diminishing role, the ‘personalised’ approach to cancer treatment and PTX’s CAR-T innovations
Health & Biotech
Prescient partners with global cancer heavyweight to develop new treatments
Health & Biotech
Prescient gears up for growth with $6.5m raise as the race to cure cancer heats up
Health & Biotech
Prescient, Antisense the only green shoots in a sea of red
News
ASX Small Cap Lunch Wrap: Who’s teaching an old dog new tricks today?
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
News